MedPath

Naltrexone

Generic Name
Naltrexone
Brand Names
Contrave, Embeda, Vivitrol
Drug Type
Small Molecule
Chemical Formula
C20H23NO4
CAS Number
16590-41-3
Unique Ingredient Identifier
5S6W795CQM
Background

Derivative of noroxymorphone that is the N-cyclopropylmethyl congener of naloxone. It is a narcotic antagonist that is effective orally, longer lasting and more potent than naloxone, and has been proposed for the treatment of heroin addiction. The FDA has approved naltrexone for the treatment of alcohol dependence.

Indication

Used as an adjunct to a medically supervised behaviour modification program in the maintenance of opiate cessation in individuals who were formerly physically dependent on opiates and who have successfully undergone detoxification. Also used for the management of alcohol dependence in conjunction with a behavioural modification program.

Associated Conditions
Alcohol Dependency, Cholestatic pruritus, Obesity, Opioid Dependence, Severe Pain
Clinical Trials
Related News

A Trial to Investigate the Effects of Cannabidiol Plus Naltrexone on Alcohol Craving in Patients With Alcohol Dependence

Phase 2
Not yet recruiting
Conditions
Alcohol Addiction
Alcoholism
Interventions
Drug: Cannabidiol capsules
Drug: Placebo
First Posted Date
2025-02-25
Last Posted Date
2025-02-25
Lead Sponsor
Central Institute of Mental Health, Mannheim
Target Recruit Count
150
Registration Number
NCT06845124
Locations
🇩🇪

Psychiatric Centre North Baden (PZN), Wiesloch, Baden-Württemberg, Germany

🇩🇪

Central Institute of Mental Health, Mannheim, Germany

The Effect of Diet or Medication to Lose Weight in People with Type 2 Diabetes and Liver Scarring

Phase 4
Recruiting
Conditions
Diabetes Mellitus, Type 2
Liver Steatoses
Overweight or Obesity
Liver Fibrosis
Hepatic Steatosis
Hepatic Fibrosis
Interventions
Other: early time restricted Mediterranean diet
First Posted Date
2025-02-25
Last Posted Date
2025-02-25
Lead Sponsor
Carmen Dietvorst
Target Recruit Count
70
Registration Number
NCT06845345
Locations
🇳🇱

Franciscus, Rotterdam, Netherlands

Metabolic and Behavioural Effects of CONTRAVE as Potential Mechanisms of Weight Loss in Adults With Obesity

Phase 4
Recruiting
Conditions
Obesity
Weight Loss
Weight Management
Dietary Intervention
Obesity/Therapy
Interventions
Drug: Placebo
Behavioral: Diet Program
First Posted Date
2025-02-05
Last Posted Date
2025-05-08
Lead Sponsor
The Royal's Institute of Mental Health Research
Target Recruit Count
40
Registration Number
NCT06809166
Locations
🇨🇦

LEAF Weight Managment Clinic, Ottawa, Ontario, Canada

🇨🇦

Behavioural and Metabolic Research Unit, Ottawa, Ontario, Canada

🇨🇦

University of Ottawa Institute of Mental Health Research, Ottawa, Ontario, Canada

Naltrexone for Overdose Prevention

Phase 2
Recruiting
Conditions
Overdose Accidental
Interventions
Behavioral: Usual Care
First Posted Date
2024-10-09
Last Posted Date
2025-04-23
Lead Sponsor
University of California, San Francisco
Target Recruit Count
100
Registration Number
NCT06633900
Locations
🇺🇸

Center on Substance Use and Health, San Francisco, California, United States

Trial to Evaluate the Effects of Naltrexone in Nonsuicidal Self-injury

Phase 2
Not yet recruiting
Conditions
Nonsuicidal Self-Injury
Interventions
Drug: Placebo
First Posted Date
2024-10-02
Last Posted Date
2024-10-04
Lead Sponsor
Seoul National University Hospital
Target Recruit Count
150
Registration Number
NCT06622239
Locations
🇰🇷

Seoul National University Hospital, Seoul, Korea, Republic of

Sex Differences in Trauma, Inflammation and Brain Function and the Implications for Treatment Efficacy in Alcohol Use Disorder

Phase 4
Recruiting
Conditions
Alcohol Use Disorder
Interventions
First Posted Date
2024-05-23
Last Posted Date
2024-07-18
Lead Sponsor
Milky Kohno
Target Recruit Count
100
Registration Number
NCT06426303
Locations
🇺🇸

VA Portland Health Care System, Portland, Oregon, United States

Study of Injectable Naltrexone and Oral Bupropion Among Cigarette Smokers With Schizophrenia

Phase 1
Recruiting
Conditions
Smoking Cessation
Interventions
First Posted Date
2024-04-18
Last Posted Date
2024-05-16
Lead Sponsor
The University of Texas Health Science Center, Houston
Target Recruit Count
20
Registration Number
NCT06374290
Locations
🇺🇸

The University of Texas health Science Center at Houston, Houston, Texas, United States

LIFT: Life Improvement Trial

Phase 2
Recruiting
Conditions
ME/CFS
Interventions
Other: Placebo
First Posted Date
2024-04-16
Last Posted Date
2025-02-10
Lead Sponsor
Brigham and Women's Hospital
Target Recruit Count
160
Registration Number
NCT06366724
Locations
🇺🇸

Brigham and Women's Hospital, Boston, Massachusetts, United States

Low Dose Naltrexone Therapy for Complex Regional Pain Syndrome

Phase 4
Conditions
Complex Regional Pain Syndrome
Chronic Pain
Complex Regional Pain Syndrome Type I
Causalgia
Complex Regional Pain Syndrome Type II
Interventions
Drug: Placebo sugar capsules
First Posted Date
2024-03-12
Last Posted Date
2024-11-19
Lead Sponsor
Hospital for Special Surgery, New York
Target Recruit Count
40
Registration Number
NCT06306157
Locations
🇺🇸

Hospital for Special Surgery, New York, New York, United States

An Acute Migraine Factorial Study

First Posted Date
2024-02-07
Last Posted Date
2024-02-07
Lead Sponsor
Allodynic Therapeutics, Inc
Target Recruit Count
92
Registration Number
NCT06245902
Locations
🇺🇸

Annette C. Toledano MD, North Miami, Florida, United States

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy